Skip to content

Board of Directors

An experienced team with a wealth of experience that provides direction for our organization.

The members of the Fidelis Animal Health board bring expertise in diverse areas of the pharmaceutical industry to help us best serve the animal health community with high-quality innovative solutions.

Meet Our Scientific Advisory Board

Meet Our Board of Directors:

MICHAEL WELLS

Chairman and Chief Executive Officer
Michael Wells has had a long and distinguished career as an entrepreneur, healthcare investor and chief executive. He is the founder and Managing Director of Princeton Biopharma Capital Partners which he created for the purpose of providing growth capital to emerging health care companies. He is also the acting Chairman and CEO of Fidelis Animal Health and non-executive Chairman of Kaleo, both portfolio companies of Princeton Biopharma Capital. Prior to creating his investment company, he was the founder and CEO of Aton Pharma, a pharmaceutical company focused on rare diseases. For his part in creating and growing this company he was named an Ernst & Young Entrepreneur of the Year in 2009 and in 2010 the company was acquired by Valeant Pharmaceuticals. After selling Aton Pharma, he partnered with Cerberus Capital Management and invested in Covis Pharma Sarl where he was a board member for five years. In 2020, Covis was sold to Apollo. His career began at Merck & Co. where he held a range of sales and marketing positions over eight years.
Michael holds a Bachelor of Science and a Master of Science from the University of Pittsburgh in addition to an MBA from The Wharton School. His current board appointments include Kaleo, Fidelis Animal Health, UPMC Hospital System and he is on the Board of Trustees at the University of Pittsburgh.

BARRY LEVINSON, PhD

Board Member and Fidelis Co-Founder
A distinguished Princeton- and Yale-educated biochemist, Dr. Barry Levinson serves as a managing director at Princeton Biopharma Capital, and is a Fidelis board member and chief development officer. He has been instrumental in bringing Ethiqa XR® to market throughout the U.S., as well as in securing additional capital for further product development and expansion at Fidelis.
Dr. Levinson’s track record of accomplishments in pharmaceuticals and biotech spans more than 40 years. Prior to co-founding Fidelis, he served as vice president of business development Valeant Pharma (now Bausch Health) and was a founding vice president (business development) and chief scientific officer at Aton Pharma.

Always having an entrepreneurial spirit, Dr. Levinson began his corporate years at the biotech start-up Ecogen. From there, he spent a decade in increasingly senior positions in cardiovascular research and business development for Berlex Labs. He then worked at two consulting firms before joining Aton.

After earning his BA with highest honors in biochemistry from Princeton, Barry went on to earn his MS and PhD degrees in molecular biophysics and biochemistry from Yale University. Mr. Wells also brings eight years of sales and marketing experience with the leading pharmaceutical manufacturer Merck to his roles at Fidelis. After his time at Merck, his first start-up venture was founding Lathian Systems Inc. to provide online data and marketing services to pharmaceutical and biotechnology companies. In addition to serving on the Fidelis Board of Directors and as a University of Pittsburgh Trustee, Mr. Wells currently holds board positions with Covis Pharma SARL, Valeo Pharmaceuticals, and PhotoSonix Medical. He earned BS and MS degrees from the University of Pittsburgh and an MBA from The Wharton School.

ANDREW MIDLER

Board Member
Andrew Midler is the founder and a managing member of Savitr Capital, a healthcare venture investment firm. Previously, he founded Standard Pacific Capital and served as its chief executive officer and chief information officer. During his tenure, the firm grew to more than $5 billion in assets with a global team of 100 people.
Prior to founding Standard Pacific, Mr. Midler served as the director of equity portfolio management at CS First Boston and as a global hedge fund manager for Odyssey Partners. His early career experience included serving as a portfolio manager at Fidelity Investments.

Mr. Midler holds an MBA from Harvard University and MA and BA degrees in political science from Stanford University.

DENNIS STEADMAN

Board Member

Dennis Steadman brings a wealth of boardroom and corporate executive experience ranging from creating and leading start-up life sciences companies, to leading large animal health organizations at national, international, and global levels. He also serves on the board of Serene LLC, 3D Therapeutics, is chairman of the board of Exubrion Therapeutics, Inc. and is past board chairman of Piedmont Animal Health.

As an accomplished life sciences entrepreneur, Mr. Steadman has founded multiple companies including two in animal health, Exubrion Therapeutics (board chair) and Velcera Pharmaceuticals (CEO). Exubrion has developed and markets a unique canine osteoarthritis treatment, and Mr. Steadman led Velcera from conception and capital funding through to acquisition by a NYSE-traded strategic player.

Mr. Steadman also brings insights from his experience in leading pharmaceutical companies to his board position at Fidelis. He is former vice president (North American) for Merial Animal Health and successfully built the Australasia region and led the US business at Merck Animal Health.

With a BS in business management and an MS in agricultural economics from The Pennsylvania State University, Mr. Steadman also holds a certificate in executive finance from Harvard Business School.

We’re committed to leading the industry with quality-driven therapeutics.

See our pipeline